Prognostic factors in patients with pathological stage I non-seminomatous testicular germ cell tumors and tumor recurrence during follow-up

P. Albers, W. T. DeRiese, T. M. Ulbright, J. P. Donohue, R. S. Foster

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Clinical staging in patients with stage I nonseminomatous germ cell tumors (NSGCTs) of the testis fails in 30% to correctly assess pathological stage since microscopic and small-volume retroperitoneal disease is not detectable on computed tomography of the abdomen. Patients staged by retroperitoneal lymph node dissection as pathological stage I incur a distant (chest or serological) tumor relapse rate of 7-15% during follow-up. Recently, we reported on new risk factors as predictors of pathological stage by flow cytometric DNA analysis in clinical stage I patients. These same methods were applied to a group of 14 pathological stage I patients who subsequently had either chest or serological recurrence. The findings in this group of patients were compared with those in a group of 47 pathological stage I patients who did not experience recurrence. In pathological stage I NSGCT patients with distant (chest or serological) tumor relapse, we found by histological evaluation and DNA analysis of the original orchiectomy specimen proliferative tumor activity to be significantly predictive of relapse. Much as proliferative activity of the primary tumor is predictive of retroperitoneal metastasis, it may be a predictor of recurrence in pathological stage I patients.

Original languageEnglish (US)
Pages (from-to)211-213
Number of pages3
JournalUrological Research
Volume23
Issue number4
DOIs
StatePublished - Aug 1 1995

Fingerprint

Recurrence
Neoplasms
Thorax
Orchiectomy
Testicular Germ Cell Tumor
Nonseminomatous germ cell tumor
DNA
Lymph Node Excision
Abdomen
Testis
Tomography
Neoplasm Metastasis

Keywords

  • Flow cytometry
  • Non-seminomatous testicular germ cell tumors
  • Prognostic parameters
  • Tumor recurrence

ASJC Scopus subject areas

  • Urology

Cite this

Prognostic factors in patients with pathological stage I non-seminomatous testicular germ cell tumors and tumor recurrence during follow-up. / Albers, P.; DeRiese, W. T.; Ulbright, T. M.; Donohue, J. P.; Foster, R. S.

In: Urological Research, Vol. 23, No. 4, 01.08.1995, p. 211-213.

Research output: Contribution to journalArticle

@article{15a41877f57c424190ba49313afa6a6e,
title = "Prognostic factors in patients with pathological stage I non-seminomatous testicular germ cell tumors and tumor recurrence during follow-up",
abstract = "Clinical staging in patients with stage I nonseminomatous germ cell tumors (NSGCTs) of the testis fails in 30{\%} to correctly assess pathological stage since microscopic and small-volume retroperitoneal disease is not detectable on computed tomography of the abdomen. Patients staged by retroperitoneal lymph node dissection as pathological stage I incur a distant (chest or serological) tumor relapse rate of 7-15{\%} during follow-up. Recently, we reported on new risk factors as predictors of pathological stage by flow cytometric DNA analysis in clinical stage I patients. These same methods were applied to a group of 14 pathological stage I patients who subsequently had either chest or serological recurrence. The findings in this group of patients were compared with those in a group of 47 pathological stage I patients who did not experience recurrence. In pathological stage I NSGCT patients with distant (chest or serological) tumor relapse, we found by histological evaluation and DNA analysis of the original orchiectomy specimen proliferative tumor activity to be significantly predictive of relapse. Much as proliferative activity of the primary tumor is predictive of retroperitoneal metastasis, it may be a predictor of recurrence in pathological stage I patients.",
keywords = "Flow cytometry, Non-seminomatous testicular germ cell tumors, Prognostic parameters, Tumor recurrence",
author = "P. Albers and DeRiese, {W. T.} and Ulbright, {T. M.} and Donohue, {J. P.} and Foster, {R. S.}",
year = "1995",
month = "8",
day = "1",
doi = "10.1007/BF00393300",
language = "English (US)",
volume = "23",
pages = "211--213",
journal = "Urolithiasis",
issn = "2194-7228",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Prognostic factors in patients with pathological stage I non-seminomatous testicular germ cell tumors and tumor recurrence during follow-up

AU - Albers, P.

AU - DeRiese, W. T.

AU - Ulbright, T. M.

AU - Donohue, J. P.

AU - Foster, R. S.

PY - 1995/8/1

Y1 - 1995/8/1

N2 - Clinical staging in patients with stage I nonseminomatous germ cell tumors (NSGCTs) of the testis fails in 30% to correctly assess pathological stage since microscopic and small-volume retroperitoneal disease is not detectable on computed tomography of the abdomen. Patients staged by retroperitoneal lymph node dissection as pathological stage I incur a distant (chest or serological) tumor relapse rate of 7-15% during follow-up. Recently, we reported on new risk factors as predictors of pathological stage by flow cytometric DNA analysis in clinical stage I patients. These same methods were applied to a group of 14 pathological stage I patients who subsequently had either chest or serological recurrence. The findings in this group of patients were compared with those in a group of 47 pathological stage I patients who did not experience recurrence. In pathological stage I NSGCT patients with distant (chest or serological) tumor relapse, we found by histological evaluation and DNA analysis of the original orchiectomy specimen proliferative tumor activity to be significantly predictive of relapse. Much as proliferative activity of the primary tumor is predictive of retroperitoneal metastasis, it may be a predictor of recurrence in pathological stage I patients.

AB - Clinical staging in patients with stage I nonseminomatous germ cell tumors (NSGCTs) of the testis fails in 30% to correctly assess pathological stage since microscopic and small-volume retroperitoneal disease is not detectable on computed tomography of the abdomen. Patients staged by retroperitoneal lymph node dissection as pathological stage I incur a distant (chest or serological) tumor relapse rate of 7-15% during follow-up. Recently, we reported on new risk factors as predictors of pathological stage by flow cytometric DNA analysis in clinical stage I patients. These same methods were applied to a group of 14 pathological stage I patients who subsequently had either chest or serological recurrence. The findings in this group of patients were compared with those in a group of 47 pathological stage I patients who did not experience recurrence. In pathological stage I NSGCT patients with distant (chest or serological) tumor relapse, we found by histological evaluation and DNA analysis of the original orchiectomy specimen proliferative tumor activity to be significantly predictive of relapse. Much as proliferative activity of the primary tumor is predictive of retroperitoneal metastasis, it may be a predictor of recurrence in pathological stage I patients.

KW - Flow cytometry

KW - Non-seminomatous testicular germ cell tumors

KW - Prognostic parameters

KW - Tumor recurrence

UR - http://www.scopus.com/inward/record.url?scp=0029163162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029163162&partnerID=8YFLogxK

U2 - 10.1007/BF00393300

DO - 10.1007/BF00393300

M3 - Article

C2 - 8533205

AN - SCOPUS:0029163162

VL - 23

SP - 211

EP - 213

JO - Urolithiasis

JF - Urolithiasis

SN - 2194-7228

IS - 4

ER -